Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1-Year Safety Study of Duloxetine in Fibromyalgia
NCT00125892Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in fibromyalgia (FM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Safety and tolerability at 1 year, Brief Pain Inventory Average Pain Score at 1 year and 1 more. Started Jul 2005; status: completed.
02
Drugs
duloxetine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT00125892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125892.